Early Access — free while we kick the tires
EdgarHawk

Madryn Asset Management, LP

10% Owner

10% Owner

Latest: Insider buying · March 2026

2 filings analyzed · 2 companies · Latest 2026-03-30

Companies

Company Buys Sells Direction
Venus Concept Inc. VERO 2 0 Net buying
Neuronetics, Inc. STIM 0 3 Net selling

Activity

March 2026
2026-03-30 Venus Concept Inc. VERO
critical
Buy
37,537,187 shares
$1,500,000
Significance 8/10

10% owner Madryn Asset Management buys 37,537,187 shares for $1,500,000.00 at $0.04; stock now -96.5% from 52-week high at $0.31

Madryn Asset Management, a 10% owner, executed 2 purchases totaling 37,537,187 shares for $1,500,000.00 on 2026-03-26, increasing its position by 368517.4% from 10,186 shares pre-transaction. The purchases occurred at $0.04 per share, while the stock currently trades at $0.31—reflecting a 90-day decline of -80.8% and a 52-week decline of -96.5% from its high of $8.93. Venus Concept Inc. reported a net loss of $-22,565,000.00 on revenue of $13,776,000.00 in the latest quarter, with annual revenue growth of -15.1% and a market cap of only $576,328.13, indicating a company in severe distress. This large accumulation by a major shareholder in a deeply depressed, cash-negative enterprise with collapsing revenue growth and minimal market capitalization warrants close investor scrutiny of restructuring risks, capital adequacy, and potential dilution mechanisms.

August 2025
2025-08-12 Neuronetics, Inc. STIM
high
Sell
3,500,000 shares
$13,020,000
Significance 7/10

10% owner Madryn Asset Management sells 3,500,000 shares at $3.72 for $13.0M, reducing stake 60.8% to 2.26M shares

Madryn Asset Management executed 3 separate sales totaling 3,500,000 shares for $13,020,000.00 at $3.72 per share on 2025-08-08, substantially reducing its position from 5,761,168 shares to 2,261,168 shares. This 60.8% reduction in holdings represents a meaningful exit by a 10% owner during a period when the company is unprofitable (net income $-10,120,000.00 over its most recent full fiscal year) and trading 28.8% below its 52-week high of $5.42. The multi-tranche execution on a single day and significant scale raise questions about liquidity management and the investor's forward outlook for the unprofitable medtech company.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access